Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-702 plus Irinotecan in Advanced Gastric Cancer
NCT05750290Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CKD-702 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Best Objective Response Rate at 24 weeks. Started Dec 2022; status: recruiting.
02
Drugs
CKD-702
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05750290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750290.